The possible beneficial role of the regular use of potent mouthwash solutions in the treatment of COVID-19
Not Applicable
Completed
- Conditions
- COVID-19 (SARS-CoV-2 infection)Infections and Infestations
- Registration Number
- ISRCTN10197987
- Lead Sponsor
- Hamad Medical Corporation
- Brief Summary
2020 Preprint results in https://doi.org/10.1101/2020.11.27.20234997 non-peer-reviewed results in preprint (added 16/03/2021)
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
1. Age 18 years and older
2. COVID-19 reported via positive PCR within 2 weeks of admission
3. Conscious, oriented and can comprehend the study purpose and risks
Exclusion Criteria
1. Pregnancy (females)
2. Intubated (at the time of recruitment) or had any reported cognitive impairment that can prevent proper comprehension of the study or communicating side effects
3. Contra-indication for mouth wash use, e.g. reported allergies to the solution constituents, recent facial/head injuries, maxillofacial conditions
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <br> 1. Recovery assessed using clinical improvement along with a negative COVID RT-PCR test at 5 and 15 days of starting treatment<br> 2. Changes in the CT-values of COVID-19 RT-PCR inconclusive test at 5 and 15 days of starting treatment<br>
- Secondary Outcome Measures
Name Time Method <br> 1. Clinical symptoms assessed using the Sore Throat Assessment Tool for the first 5 days<br> 2. COVID progression (ICU intubation vs discharge or transfer to quarantine) recorded by reviewing medical records within the study duration<br> 3. Hospital stay measured using (days) at discharge; or at the end of study for those remained admitted<br> 4. Disposition type (discharged/death) measured using hospital records entries at the time of discharge, or reported mortality during hospital stay<br>